NR4A1 and breast carcinoma: Capivasertib (TruqapTM) is used in combination with fulvestrant (FaslodexTM) for the treatment of patients with hormone-receptor-positive, human-epidermal-growth-factor-receptor-2-negative breast cancer with metastatic disease.